Effects of Silymarin on Treatment Naand#239;ve Patients with Chronic Hepatitis B Infection-A Randomized Controlled Trial

Okonkwo Uchenna C; Aluka Anthony2; Ezedinachi Emmanuel

ISSN: 2332-0877

Journal des maladies infectieuses et de la thérapie

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Politiques et éthique de publication

Indexé dans

Index Copernic
Google Scholar
Ouvrir la porte J
Recherche de référence
Université Hamdard
EBSCO AZ
OCLC-WorldCat
Publons
Euro Pub
ICMJE

Liens utiles

Revues en libre accès

Partager cette page

Abstrait

Effects of Silymarin on Treatment Naïve Patients with Chronic Hepatitis B Infection-A Randomized Controlled Trial

Okonkwo Uchenna C, Aluka Anthony2 and Ezedinachi Emmanuel

Background: Silymarin, an extract of milk thistle (silybum marianum) is widely used in the treatment of patients with chronic liver disease yet its beneficial effects remain controversial.

Aim: To determine the effect of silymarin on liver biochemistry and health related quality of life (HRQOL) in treatment naïve patients with chronic hepatitis B infection.

Methods: This was a double-blind randomized placebo-controlled trial conducted at the University of Calabar Teaching Hospital, Cross river state. Patients with chronic hepatitis B were randomized to receive silymarin or placebo for 4 weeks. Their liver function tests and HRQOL were assessed at baseline and post-treatment.

Results: Eighty-six persons were enrolled into the study. Seventy-nine completed the study. Silymarin use was associated (p<0.05) with improvement in serum alanine and aspartate aminotransferase and HRQOL from baseline but not with serum bilirubin and alkaline phosphatase.

Conclusion: Silymarin use among patients with chronic hepatitis B is associated with improvement in liver function tests especially markers of liver inflammation and HRQOL.